Hillel Tobias, MD
Gastroenterology · New York, NYNPI 1780608422
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $98,565 of the $110,803 with a category attached, or 89.0%. Gilead accounts for 77.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $50,150 and has fallen 99.5% since, to $268 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $488.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$85K
- AbbVie$9K
- Shionogi Inc$5K
- Intercept Pharmaceuticals, Inc.$5K
- Dova Pharmaceuticals$4K
- Bristol Myers Squibb$965
- plus $2K from 18 others
Across 42 payments — averaging $1994.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$39K
- Gilead$27K
- Bristol Myers Squibb$6K
- Intercept Pharma Europe Ltd.$6K
- AbbVie$5K
What the payments were for
- Consulting fees$7501%
- Speaking & faculty fees$98,56589%
- Travel & lodging$5,1775%
- Food & beverage$6,1726%
- Education$1390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 80 | $85,368 |
| AbbVie(2 entities) | 25 | $8,719 |
| Shionogi Inc | 5 | $4,918 |
| Intercept Pharmaceuticals, Inc. | 8 | $4,675 |
| Dova Pharmaceuticals | 6 | $4,056 |
| Bristol Myers Squibb | 5 | $965 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $713 |
| QOL Medical, LLC | 23 | $351 |
| Madrigal Pharmaceuticals | 2 | $268 |
| Johnson & Johnson | 16 | $265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $103 |
| Mallinckrodt Hospital Products Inc. | 3 | $82 |
| Ironwood Pharmaceuticals, Inc | 3 | $62 |
| Merck | 3 | $45 |
| Phadia US Inc. | 1 | $33 |
| AstraZeneca | 1 | $31 |
| Concordia Pharmaceuticals Inc. | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Romark Laboratories, LC | 1 | $16 |
| UCB, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$110,803 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 17 | $58,332 |
| MounjaroTirzepatide | 18 | $18,136 |
| LinzessLinaclotide | 11 | $6,768 |
| Ursodiol | 24 | $5,013 |
| Pantoprazole Sodium | 13 | $308 |
| Spironolactone | 20 | $243 |
| Rosuvastatin Calcium | 12 | $137 |
| Furosemide | 22 | $131 |
| Omeprazole | 32 | $129 |
| Atorvastatin Calcium | 12 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $713 | $58,33217 claims |
| AbbVieLinzess | $8,719 | $6,76811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.